Abby Hardy, Author at BioTuesdays

Developments

Marinus Pharma reports positive topline data from Phase 2 epileptic seizure trial

Marinus Pharmaceuticals (NASDAQ:MRNS) reported positive topline results from its Phase 2 trial of intravenous (IV) ganaxolone for the treatment of refractory status epilepticus (RSE). Status epilepticus is a prolonged...

September 26, 2019

Developments

Urogen Pharma reports data from two urinary tract cancer trials

UroGen Pharma (NASDAQ:URGN) reported results from its Phase 3 and Phase 2b trials of its mitomycin gel in patients with low-grade upper tract urothelial cancer (UTUC) and intermediate risk low-grade non-muscle invasive...

September 25, 2019

Executive Moves

Catabasis Pharma names Andrew Komjathy as chief commercial officer

Andrew Komjathy Catabasis Pharmaceuticals (NASDAQ:CATB) appointed Andrew Komjathy as its chief commercial officer. Catabasis’ lead program is edasalonexent for the treatment of Duchenne muscular dystrophy (DMD). The...

September 25, 2019

Developments

Achillion gets FDA breakthrough therapy designation for danicopan

Achillion Pharmaceuticals’ (NASDAQ:ACHN) danicopan received FDA breakthrough therapy designation for the treatment of paroxysmal nocturnal hemoglobinuria (PNH). In PNH, the complement system destroys red blood cells in...

September 25, 2019

Developments

Mateon Therapeutics gets FDA pediatric disease designation for DIPG drug candidate

Mateon Therapeutics’ (NASDAQ:MATN) OT-101 received FDA pediatric disease designation for the treatment of diffuse intrinsic pontine glioma (DIPG). DIPG is a rare pediatric brainstem tumor that has a very low survival...

September 24, 2019

Developments

Ovid Therapeutics reports positive initial data from Phase 2 epilepsy trial

Ovid Therapeutics (NASDAQ:OVID) reported positive initial data from its Phase 2 study of soticlestat, a cholesterol 24-hydroxylase inhibitor, in patients with rare developmental and epileptic encephalopathies (DEE). ...

September 24, 2019

Developments

Aldeyra gets FDA fast track designation for vitreoretinopathy drug candidate

Aldeyra Therapeutics’ (NASDAQ:ALDX) ADX-2191 received FDA fast track designation for the prevention of proliferative vitreoretinopathy (PVR). PVR is an inflammatory disorder of the retina that leads to severe retinal...

September 24, 2019

Developments

Ocular Therapeutix doses first patient in Phase 3 allergic conjunctivitis trial

Ocular Therapeutix (NASDAQ:OCUL) has dosed the first patients in its Phase 3 efficacy trial of DEXTENZA for the treatment of symptoms of allergic conjunctivitis (AC). DEXTENZA is a corticosteroid that is FDA-approved...

September 24, 2019

Developments

Zynerba Pharma reports positive topline Phase 2 Zygel efficacy data

Zynerba Pharmaceuticals (NASDAQ:ZYNE) reported positive topline efficacy results, along with safety profile issues, from its open label Phase 2 study assessing the safety and efficacy of Zygel in developmental and...

September 19, 2019

Developments

Zenabis outperforms revised cannabis design capacity by 41% in August

Zenabis Global’s (TSX:ZENA) cultivation output in August 2019 was 1,996 kg of dried cannabis, 40.9% greater than its revised design capacity and 26.4% greater than its Aug. 6 revised forecast output of 1,579 kg of dried...

September 18, 2019

Author - Abby Hardy

Marinus Pharma reports positive topline data from Phase 2 epileptic seizure trial

Urogen Pharma reports data from two urinary tract cancer trials

Catabasis Pharma names Andrew Komjathy as chief commercial officer

Achillion gets FDA breakthrough therapy designation for danicopan

Mateon Therapeutics gets FDA pediatric disease designation for DIPG drug candidate

Ovid Therapeutics reports positive initial data from Phase 2 epilepsy trial

Aldeyra gets FDA fast track designation for vitreoretinopathy drug candidate

Ocular Therapeutix doses first patient in Phase 3 allergic conjunctivitis trial

Zynerba Pharma reports positive topline Phase 2 Zygel efficacy data

Zenabis outperforms revised cannabis design capacity by 41% in August

Subscribe